Levamisole does not produce chromosome fractures

Area of Science:

• Pharmacology
• Genetics
• Toxicology

Background:

• Levamisole is structurally similar to metronidazole.
• Metronidazole is known to cause chromosome alterations in various species.
• The potential genotoxicity of levamisole requires investigation.

Purpose of the Study:

• To evaluate the clastogenic potential of levamisole in mice.
• To compare the effects of levamisole and metronidazole on chromosome integrity.

Main Methods:

• BALB/c mice were administered daily subcutaneous injections of levamisole or metronidazole for five consecutive days.
• Pharmacological doses were used: 2.5 µg/g body weight for levamisole and 6.2 µg/g for metronidazole.
• Hematopoietic sternum cells were analyzed for chromosome fractures on each day of the study.

Main Results:

• Control mice exhibited no chromosome fractures.
• Metronidazole administration resulted in a dose-dependent increase in chromosome fractures, reaching 9.10% by day five.
• Levamisole administration did not result in any observable chromosome fractures throughout the study period.

Conclusions:

• Levamisole does not appear to be clastogenic in mice under the tested conditions.
• Metronidazole demonstrated significant genotoxic effects, confirming its known clastogenic activity.
• Further research may be warranted to fully elucidate the genotoxic profile of levamisole.